For the second time in recent weeks, a small, privately held drug maker with a piece of the action in two hot markets is being scrutinized by lawmakers over its pricing.
In the latest episode, US Senator Chuck Grassley (R-Iowa) wants Kaleo to explain why it set a $4,500 list price for the Auvi-Q allergic reaction device that is competing with EpiPen. The move is actually part of a complicated pricing strategy that may appeal to some consumers, but not so much to insurers.
Kaleo is selling its device for $360 in cash to people without insurance. But the company will cover the cost entirely for those with high-deductible insurance plans or who have a household income less than $100,000 and also lack insurance.
Reading their $trategy, it seems that ER’s, municipalities that supply their police and other services would be taking it on the chin. No insurance for them, just a co$t of doing business. Or did I miss something?
Comments are closed.